The Characteristics of Blood Glucose Profile and the Changes of Hormones in PPDM-C Population

The Characteristics of Blood Glucose Profile and the Changes of Endogenous and Exogenous Hormones in Patients with Post-chronic Pancreatitis Diabetes Mellitus

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06826729

Enrollment

2000

Registered

2025-02-14

Start date

2025-02-11

Completion date

2027-07-01

Last updated

2025-02-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Pancreatitis, Diabetes

Keywords

chronic pancreatitis, PPDM-C, CGM

Brief summary

The purpose of this study was to explore the characteristics of blood glucose spectrum, changes of endocrine/exocrine pancreatic function and the correlation between them in patients with PPDM-C.

Detailed description

The benefits of this study to participants include: 1. It will help to make early diagnosis or risk screening for the potential related risks and concomitant diseases of the disease; 2. Provide necessary suggestions for the treatment and intervention of the disease, or provide useful information for the related research of the disease. 3. We will provide Abbott version h dynamic glucose meter and assessment of internal and external secretion function. The researcher will provide professional endocrine related lifestyle and drug guidance for the subjects according to their CGMS data. The risks that this study may bring to participants are: There may be some very small risks in specimen collection, including transient pain, local cyanosis, etc. a few people will have mild dizziness or extremely rare needle infection.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Male or female Chinese subjects; * Was ≥ 18 years old when signing the informed consent; * Patients with complete diagnosis of chronic pancreatitis; ④ Those who voluntarily signed informed consent; ⑤ Those who complete serum samples in multiple centers and put them into storage.

Exclusion criteria

* Patients with impaired glucose tolerance but undiagnosed diabetes; * Patients with T1DM related autoimmune markers or other types of DM; * Patients with autoimmune pancreatitis, recurrent acute pancreatitis or acute onset of chronic pancreatitis; * Patients who underwent pancreatic surgery or related invasive procedures during treatment; * Previous or current malignant tumor; ⑥ Pregnancy or lactation; ⑦ Suffering from severe heart, liver or kidney dysfunction or malignant disease; ⑧ Failure to sign informed consent for cognitive impairment or other reasons.

Design outcomes

Primary

Measure	Time frame
Blood glucose profile characteristics of patients with PPDM-C	From February 2025 to December 2025

Outcome results